ControlPoint, Inc. Names Initial Board Members
Campbell, Calif. – ControlPoint, Inc., an animal diagnostics company focused on developing tests that could be used by anyone, anywhere, has announced its initial board members to lead the company’s early phases.
Paul Hays and Steve Schram were appointed to the board for their extensive experience in animal health and commercial launch strategy. “I am pleased to have these two experienced professionals join me at ControlPoint as we finalize our products and develop our go-to-market strategy,” said ControlPoint CEO Paula Walker. “When pet health is at risk, fast, accurate testing and diagnoses are critical. ControlPoint will bring innovative new tools to veterinarians and others who care for pets.”
Formed in 2020, ControlPoint is currently developing a point-of-care test for multiple pathogens by which veterinarians can be confident in their diagnosis of kennel cough. Veterinarians will have same day test results allowing veterinarians to expand their practice, increase their margins and provide better patient care.
Hays is president and CEO of Med-Pharmex, Inc., a developer, manufacturer, and distributor of veterinary drugs for companion animals and livestock located in Pomona, Calif. He has passionately contributed 38 years to the animal health industry and has earned a reputation for transforming businesses.
Schram is an experienced CEO/sales and marketing executive with a demonstrated 38-year history of leading businesses in the pharmaceuticals and biologics industry. He has worked with three animal health companies throughout his career: Norbrook Animal Health, AgriLabs/Benchmark/VaxLiant Companies, and Syntex Animal Health.
Both new board members are skilled in go-to-market strategy and implementation of veterinary products, with successful histories in business development.
“We have an opportunity to ensure the lives and well-being of animals are greatly improved through the point-of-care tests we are currently developing,” added Walker. “Our board members will play an important role in expediting our launch and ensuring success.”
Paul Hays
Prior to joining Med-Pharmex, Hays was president and CEO for Virbac’s North American business, leading the acquisition of SENTINEL brand parasiticide, strengthening the commercial organization and leading the turnaround of a Warning Letter at their FDA production facilities. He has also served as chief commercial officer of Vets Plus and vice president of Global Diagnostics at Pfizer Animal Health (Zoetis) where he led their entry into veterinary diagnostics through the integration of Synbiotics Corporation into Pfizer’s global business. Hays was Synbiotics’ president and CEO for eight years, first as a public company, which he took private and finally planned and led the sale to Pfizer.
Preceding those roles, Hays held progressive senior management roles with Boehringer Ingelheim Vetmedica including vice president of sales and marketing where he founded both their equine and swine business units. The swine business unit grew rapidly under his leadership with the launch of the firstPRRS and Ileitis vaccines and through the acquisitions of Fermenta Animal Health and NOBL Laboratories. Subsequently, he worked in Germany headquarters as corporate VP of marketing and area businesses, then returned to lead the U.S. business as executive vice president of U.S. business operations. Earlier in his career, he was part of the U.S. start-up team for CIBA Animal Health (later, Novartis) and began his career as sales representative for Coopers Animal Health. He earned a bachelor’s degree in animal science from the University of Missouri.
Steve Schram
Schram formed Schram Consulting in 2021 after a 38-year career with three animal health companies over his career.
Norbrook Animal Health: Schram was vice president of sales and marketing for the Americas for Norbrook starting in 2018. During his tenure with Norbrook, he led seven new generic launches in the North American market. Responsibilities included leading the companion and food animal sales, marketing, and technical services teams in North and South America.
AgriLabs/Benchmark/VaxLiant Companies: Schram was CEO of AgriLabs for 23 years until 2017, when he led the exit strategy for the board selling all the companies to Huvepharma in 2017. After joining the company in 1995, he was instrumental in making significant investments in R&D to develop new generic pharmaceuticals and novel biological products. Under his leadership, the company also secured licensing deals that included several domestic and international arrangements, leading to successful introductions of new products to the United States marketplace. In 2014, the company purchased a contract research company, Benchmark Biolabs, a vaccine plant, Antelope Valley Bios and co-founded a vaccine adjuvant business VaxLiant. In 2016, AgriLabs built a new USDA licensed vaccine facility.
Syntex Animal Health: Schram began his animal health career in 1983 as a territory manager. Over the next 12 years, He held several sales and marketing positions. In his last position as business unit manager for Anthelmintics, he was part of the team that transitioned the business to Fort Dodge Animal Health in 1995.
ControlPoint is on a mission to improve the health and well-being of animals around the globe. For more information on the company, visit www.controlpointdx.com
For press inquires contact info@controlpointdx.com or Sharon Polk, 913-221-5834; spolk@dmgcommunication.com